Glaucoma is a disease of the optic nerve which is estimated to affect 79.6 million people world-wide and, if left untreated, causes irreversible damage.In m
Police speak on fewer gang offences in Hawke s Bay
26 Feb, 2021 03:30 AM
6 minutes to read
Armed police swarm Taradale in 2020 after shots are fired near the CBD during a gang fight. Photo / Warren Buckland
Armed police swarm Taradale in 2020 after shots are fired near the CBD during a gang fight. Photo / Warren Buckland
The increasing use of firearms in Hawke s Bay gang disputes has put gang members in the sights of a new police operation. But the sheer number of Mongrel Mob chapters, and a rise in public displays of violence with rivals Black Power, mean the challenge for officers on the streets is significant, police say.
Addressing a webinar on the Budget announcements for the Department of Financial Services (DFS), the Prime Minister said that reforms in the banking sector will continue.
About PFIC
Progressive familial intrahepatic cholestasis (PFIC) is a rare disorder that causes progressive, life-threatening liver disease. Patients have impaired bile flow, or cholestasis, caused by genetic mutations. The resulting bile build-up in liver cells causes liver disease and symptoms. The most prominent and problematic ongoing manifestation of the disease is pruritus, or intense itching, which often results in a severely diminished quality of life. Other symptoms include jaundice, poor weight gain and slowed growth. In many cases, PFIC leads to cirrhosis and liver failure within the first 10 years of life, and nearly all people with PFIC require treatment before age 30. There are no drugs currently approved for PFIC, only surgical options that include partial external biliary diversion (PEBD) and liver transplantation. Additional information on PFIC is available at https://www.pficvoices.com.
(2)
Wearable cardiac monitoring solution enables early detection and treatment of arrhythmia based on risk factors, according to results of the SCREEN-AF study published in JAMA Cardiology iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the results of a brand new SCREEN-AF study, led by researchers at Sunnybrook Health Sciences Centre in Toronto, Canada and University Hospital in Leipzig, Germany, which was published in
JAMA Cardiology
The transatlantic clinical trial found that Zio by iRhythm, an ambulatory cardiac monitoring solution, led to a tenfold increase in the detection of atrial fibrillation (AF) versus patients receiving standard clinical care. One out of every 20 patients in the heart monitoring group was found to have a new diagnosis of atrial fibrillation and, as a result, 75 percent of those patients were subsequently prescribed a blood thinner medication for